Skip to content
AnalystLens

Halozyme Therapeutics Quarterly Report for Q3 Ended Sep 30, 2026

Filing Date
Filed November 5, 2026
Period End
September 30, 2026
Security
HALO
One revenue dollarkept$0.50
In the record · 2016–202610-K1110-Q338-K141

HALO filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 141 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jul ’17Jul ’17
  2. Leadership change8-K · Feb ’20Feb ’20
  3. Deal closed8-K · May ’22May ’22
  4. Leadership change8-K · Dec ’25Dec ’25

Summary

Summary of the 10-Q filed November 5, 2026. Cited figures are marked; the original filing is the authoritative source.

Halozyme Therapeutics (HALO) reported a strong third quarter for 2026, demonstrating significant growth in revenues and robust operational performance.

Total revenues surged by 44% year-over-year to $493.0 milliona, primarily driven by a substantial 44% increase in royalty income, reaching $341.0 million. This growth was fueled by strong sales of key partner products utilizing Halozyme's ENHANZE technology, notably VYVGART Hytrulo and DARZALEX SC. Product sales also saw a significant uplift of 46% to $137.3 million, largely attributed to increased demand for bulk rHuPH20 and continued market growth for proprietary product XYOSTED.

Operating expenses increased by 45% to $198.0 millionb, impacted by higher cost of sales, increased amortization of intangibles due to recent acquisitions (Elektrofi and Surf Bio), and elevated research and development and SG&A expenses. Despite the rise in operating expenses, the company maintained strong profitability, with net income growing to $247.0 million, a 41% increase compared to the prior year's quarter, and diluted earnings per share rising to $2.01.

The company also strengthened its financial position by issuing $1.5 billionc in convertible notes in September 2026, enhancing its liquidity which stood at $1.07 billion in cash, cash equivalents, and marketable securities as of September 30, 2026. Halozyme continues to actively manage its capital structure, including ongoing share repurchase programs.

Key Highlights

  1. Total revenues grew by 44% to $493.0 million in Q3 2026 compared to Q3 2025.
  2. Royalty revenue increased by 44% to $341.0 million, driven by strong performance of partner products like VYVGART Hytrulo and DARZALEX SC.
  3. Product sales, net, increased by 46% to $137.3 million, bolstered by bulk rHuPH20 sales and XYOSTED.
  4. Net income rose by 41% to $247.0 million, demonstrating strong profitability.
  5. Diluted earnings per share increased to $2.01 from $1.43 in the prior year's quarter.
  6. The company strengthened its liquidity by issuing $1.5 billion in 1.50% Convertible Senior Notes due 2033.
  7. Cash, cash equivalents, and marketable securities stood at $1.07 billion as of September 30, 2026, indicating a healthy liquidity position.

Follow one dollar

Of each $1.00 of revenue in Q3 FY2026, Halozyme Therapeutics kept $0.50.

  1. Revenue$493.0M100.0%
  2. Cost of revenue−$82.5M16.7%
  3. Gross profit$410.5M83.3%
  4. Operating costs−$115.5M23.4%
  5. Operating income$295.0M59.8%
  6. Interest, other & tax−$47.9M9.7%
  7. Net income$247.0M50.1%
Computed from 10-QQ3 FY2026filed November 5, 2026Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Financial Statements

Q3 FY2026 against Q3 FY2025

Line itemQ3 FY2026Q3 FY2025Change
Revenue$492.97M$354.26M+39.2%
Cost of Revenue$82.47M$55.24M+49.3%
Gross Profit$410.50M$299.02M+37.3%
R&D Expenses$27.78M$17.25M+61.0%
SG&A Expenses$58.24M$46.09M+26.4%
Operating Expenses$198.00M$136.34M+45.2%
Operating Income$294.97M$217.92M+35.4%
Net Income$247.05M$175.22M+41.0%
EPS (Basic)$2.17$1.49+45.6%
EPS (Diluted)$2.01$1.43+40.6%
Shares Outstanding (Basic)113.80M117.22M−2.9%
Shares Outstanding (Diluted)122.61M122.33M+0.2%

Frequently Asked Questions

  1. What was the primary driver of Halozyme's revenue growth in the third quarter of 2026?

    The primary driver of Halozyme's revenue growth was a significant increase in royalty revenue, up 44% to $341.0 million. This growth was mainly attributed to strong sales performance from key partner products utilizing their ENHANZE technology, such as VYVGART Hytrulo and DARZALEX SC.

  2. How did the acquisitions of Elektrofi and Surf Bio impact the company's financial results?

    The acquisitions of Elektrofi (in November 2025) and Surf Bio (in December 2025) contributed to an increase in operating expenses, specifically in amortization of intangibles, research and development, and selling, general and administrative costs. These acquisitions are part of Halozyme's strategy to expand its drug delivery technology offerings.

  3. What is Halozyme's current liquidity position?

    As of September 30, 2026, Halozyme maintained a strong liquidity position with $1.07 billion in cash, cash equivalents, and marketable securities. This is further supported by the recent issuance of $1.5 billion in convertible notes.

  4. Are there any significant upcoming milestones or events mentioned in the filing?

    The filing mentions several upcoming events, including Takeda's Biologics License Application filing for TAK-881, Janssen expanding its collaboration for an additional oncology target, Roche's FDA approval for TECENTRIQ HYBREZA, and argenx's supplemental Biologics License Application submission for VYVGART. These events highlight ongoing development and regulatory progress within Halozyme's partnerships.